Confirm GAA deficiency and the molecular diagnosis
Pompe disease should be supported by appropriate biochemical and genetic evidence before a patient commits to long-term disease-specific therapy. A German second opinion can review enzyme testing, GAA genetics and the clinical phenotype, especially when weakness has previously been labelled as an unspecified myopathy or muscular dystrophy.
- GAA enzyme-activity result and specimen method
- GAA molecular genetic report
- Age at onset and pattern of weakness
- Respiratory symptoms and testing
- Cardiac findings where relevant
- Family history and previous metabolic work-up
Separate infantile-onset from late-onset Pompe disease
Infantile-onset Pompe disease can involve severe early muscle weakness, respiratory disease and cardiomyopathy and requires specialized pediatric metabolic/neuromuscular care. Late-onset Pompe disease more often presents with progressive limb-girdle and respiratory muscle weakness. Age and phenotype affect monitoring, urgency and the appropriate clinical service.
Enzyme replacement is a long-term treatment pathway
EMA authorises Myozyme (alglucosidase alfa) and Nexviadyme (avalglucosidase alfa) for long-term enzyme replacement in Pompe disease. Both are intravenous treatments supervised by clinicians experienced in Pompe or related inherited disorders. The center should review previous response, infusion tolerance, respiratory trajectory and functional measures rather than select a product from marketing claims alone.
Pombiliti plus Opfolda is an adult late-onset pathway
EMA authorises cipaglucosidase alfa (Pombiliti) together with oral miglustat (Opfolda) for adults with late-onset Pompe disease. The combination has a specific dosing relationship and is not simply another standalone infusion. Eligibility and switching decisions should be made by a specialist who has reviewed previous ERT and the current clinical trajectory.
Respiratory assessment is central, not optional
Pompe disease can weaken the diaphragm and other respiratory muscles. Long-term review should track respiratory symptoms and objective pulmonary function and consider sleep-related hypoventilation, cough effectiveness and non-invasive ventilation when appropriate. Acute respiratory deterioration requires immediate local care rather than planned international travel.
Track motor function with reproducible measures
A meaningful treatment review compares objective function over time rather than relying only on whether the patient feels stronger or weaker. Specialist centers may use walking, timed-function, strength and respiratory measures appropriate to age and disease severity.
- Walking distance or timed mobility when applicable
- Proximal muscle strength and transfer ability
- Upper-limb and daily-living function
- Serial pulmonary-function measurements
- Use of ventilation or cough-assist devices
- Physiotherapy and orthotic requirements
Cardiac review is particularly important in early-onset disease
Pompe disease can affect cardiac muscle, especially in infantile-onset disease. Pediatric pathways therefore coordinate metabolic/neuromuscular care with cardiology as needed. Adults with cardiac symptoms or uncertain involvement may also require targeted cardiac assessment rather than assuming all weakness is skeletal-muscle only.
Infusion reactions and treatment monitoring matter
EMA product information for Pompe ERTs describes infusion-associated and hypersensitivity reactions. Long-term treatment therefore requires appropriate supervision, monitoring and a plan for managing reactions. A second opinion should include the history of infusion tolerance and any previous treatment interruption.
Medical travel should account for every-two-week therapy logistics
Several Pompe ERT pathways involve repeated infusions, commonly every other week. For an international patient, a German consultation may be most useful for diagnosis confirmation, treatment selection or response review, followed by continuing therapy closer to home when clinically and legally feasible. If treatment is to remain in Germany, ask the center to specify the recurring schedule and monitoring requirements before arranging long-term accommodation.
What to send for a German Pompe second opinion
The center needs enough information to confirm both diagnosis and treatment trajectory.
- GAA enzyme-activity report
- GAA genetic report
- Neuromuscular/metabolic specialist reports
- Current and previous ERT product, dose and infusion dates
- History of infusion reactions or antibodies if tested
- Serial pulmonary-function and sleep-study results
- Motor-function and physiotherapy assessments
- Cardiology reports and echocardiography if relevant
- Current ventilation, cough-assist and mobility equipment
- A specific question: confirm diagnosis, start ERT, switch therapy, review response or coordinate long-term care
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Myozyme (alglucosidase alfa) – EPAR — European Medicines Agency ↗
- Nexviadyme (avalglucosidase alfa) – EPAR — European Medicines Agency ↗
- Pombiliti (cipaglucosidase alfa) – EPAR — European Medicines Agency ↗
- Opfolda (miglustat) – EPAR — European Medicines Agency ↗
- Neuromuscular patient care / Pompe Therapy Center — University Hospital Bonn ↗
- Neuromuscular outpatient clinic — Heidelberg University Hospital ↗
- Pediatric metabolic medicine — Charité – Universitätsmedizin Berlin ↗